Research is shifting away from focusing on historical outcomes and being satisfied with “clinical stability” toward a focus on long-term functional outcomes in treated chronic inflammatory demyelinating polyneuropathy (CIDP) populations.
Sponsored
Advertisement
Paid content from Takeda Pharmaceuticals intended for U.S. healthcare professionals.
Advertisement
This article was sponsored by Sandoz
Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)
Advertisement
Khashayar Dashtipour, MD, PhD, director of the Division of Movement Disorders at Loma Linda University and paid consultant of Acadia Pharmaceuticals Inc., shares insights on balancing the treatment of motor and non-motor symptoms, and the importance of timely intervention for Parkinson’s disease psychosis.
Advertisement
Sponsored Article
Sponsored By Novartis
Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.
Sponsored By Novartis
Jason Freeman, MD, MBA, and Gina Mavrikis Cox, PhD, discuss a presentation from CMSC 2023 on the role of serum biomarkers in multiple sclerosis management. Sponsored by Novartis.
Sponsored Article
Sponsored by Cerevel Therapeutics
Sponsored Content
The results of a phase 4 study demonstrate the efficacy of APOKYN® (apomorphine hydrochloride injection) treatment.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
4
MDS Congress 2026: Late-Breaking Data Snapshot
5